If you have been reading about visceral adipose tissue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
== External links == Sir Howard Florey on Nobelprize.org including the Nobel Lecture, "Penicillin", 11 December 1945 Oral History: Sir Howard Florey—Interviewed by Hazel de Berg in 1967 (audio recording)
All darmstadtium isotopes are extremely unstable and radioactive; in general, the heavier isotopes are more stable than the lighter. The most stable known darmstadtium isotope, 281Ds, is also the heaviest known darmstadtium isotope; it has a half-life of 14 seconds. The isotope 279Ds has a half-life of 0.18 seconds, while the unconfirmed 281mDs has a half-life of 0.9 seconds. The remaining isotopes and metastable states have half-lives between 1 microsecond and 70 milliseconds. Some unknown darmstadtium isotopes may have longer half-lives, however. Theoretical calculation in a quantum tunneling model reproduces the experimental alpha decay half-life data for the known darmstadtium isotopes. It also predicts that the undiscovered isotope 294Ds, which has a magic number of neutrons (184), would have an alpha decay half-life on the order of 311 years; exactly the same approach predicts a ~350-year alpha half-life for the non-magic 293Ds isotope, however.
=== Music === V.I.P. (Hungarian band), a defunct pop boy group The V.I.P.'s (band), an English band of the 1960s Voices in Public, a Canadian boy group VVIP (hip-hop group), a Ghanaian hiplife band, formerly known as VIP (or Vision In Progress) V.I.P. (album), a 2000 album by Jungle Brothers, or the title track "V.I.P." (Bro'Sis song) (2003) "V.I.P" (Ice Prince song) (2013) "V.I.P" (Sid song) (2013) "VIP" (Aya Nakamura song) (2022) V.I.P., a subsidiary label of Motown Records VIP Music Records, an American record label based in New York City (founded 2004) VIP Records, a record store chain from Los Angeles, California (founded 1967) "VIP", a song by Kesha from Animal (Kesha album) The V.I.P. (The Vanilla Ice Posse), the rapper's DJs and backup dancers Victory in Praise Music and Arts Seminar Mass Choir, an organization founded by John P. Kee "V.I.P.", a song by Françoise Hardy "V.I.P.", a song by R. Kelly from R. (R. Kelly album) V.V.I.P, a 2011 EP by Seungri V.I.P. – Very Important Pony, 2025 EP by HorsegiirL
Protein-fructosamine 3-kinase (EC 2.7.1.171, FN3K, fructosamine 3-kinase) is an enzyme with systematic name ATP:(protein)-N6-D-fructosyl-L-lysine 3-phosphotransferase. This enzyme catalyses the following chemical reaction
=== Stereoisomers === In addition to distinguishing tocopherols and tocotrienols by position of methyl groups, the tocopherols have a phytyl tail with three chiral points or centers that can have a right or left orientation. The naturally occurring plant form of alpha-tocopherol is RRR-α-tocopherol, also referred to as d-tocopherol, whereas the synthetic form (all-racemic or all-rac vitamin E, also dl-tocopherol) is equal parts of eight stereoisomers RRR, RRS, RSS, SSS, RSR, SRS, SRR and SSR with progressively decreasing biological equivalency, so that 1.36 mg of dl-tocopherol is considered equivalent to 1.0 mg of d-tocopherol, the natural form. Rephrased, the synthetic has 73.5% of the potency of the natural.
Sources: en.wikipedia.org
=== Former commissioners === David Gallop was the initial chief executive officer of the restructured ARL Commission. He was previously the CEO of the NRL and his contract extension to become inaugural ARL CEO was a condition placed by News Limited with the ARL. On 5 June 2012 the ARL announced Gallop's departure from the CEO position and that he would take up a position at the FFA in 2013. David Smith was announced as the new ARL CEO in November 2012, taking charge on 1 February 2013.
In an RTG, heat generation cannot be varied with demand or shut off when not needed and it is not possible to save more energy for later by reducing the power consumption. Therefore, auxiliary power supplies (such as rechargeable batteries) may be needed to meet peak demand, and adequate cooling must be provided at all times including the pre-launch and early flight phases of a space mission. While spectacular failures like a nuclear meltdown or explosion are impossible with an RTG, there is still a risk of radioactive contamination if the rocket explodes or the device reenters the atmosphere and disintegrates. For terrestrial RTGs, damage by storms, seasonal ice, or vandalism are potential risks.
n (CH2CH2)O → (–CH2CH2–O–)n To suppress the formation of other linear polymers the reaction is carried out in a highly dilute solution. Reaction of ethylene oxide with sulfur dioxide in the presence of caesium salts leads to the formation of an 11-membered heterocyclic compound which has the complexing properties of crown ethers:
In 2008, she presented the Proms season on BBC Two; has also presented The Culture Show, BBC Young Musician of the Year and The Review Show; For Sky Arts, hosted programmes on Sky Arts 2; also presented Aida from Royal Albert Hall (March 2012) for The Rosenblatt Recitals; was named Music Broadcaster of the Year, winning the Silver Prize at the Sony Awards; has presented global opera broadcasts for Royal Opera, London, and hosted broadcasts of the Royal Shakespeare Company; in 2021, appointed Head of Arts and Classical Music TV. Matthew Kneale, writer (Jewish mother) Matthew Kramer (born 9 June 1959) author and editor of over twenty scholarly texts; philosopher and signatory of the Euston Manifesto; currently Professor of Legal and Political Philosophy at the University of Cambridge and a Fellow of Churchill College, Cambridge. He writes mainly in the areas of metaethics, normative ethics, legal philosophy, and political philosophy; Director of the Cambridge Forum for Legal and Political Philosophy; elected a Fellow of the British Academy, the United Kingdom's national academy for the humanities and social sciences. Arthur Koestler, novelist and critic Bernard Kops, poet Peter Kosminsky (born 21 April 1956) is a British writer, director, screenwriter and producer; has directed Hollywood movies such as White Oleander and television films like Warriors, The Government Inspector, The Promise, Wolf Hall and The State. Elena Lappin is a writer and editor.
Sources: en.wikipedia.org
== Chemistry == Dextromoramide is the right-handed isomer of the moramide molecule. The left-handed molecule is called levomoramide, and a mixture of the two is called racemoramide. Its full chemical name is (+)-1-(3-Methyl-4-morpholino-2,2-diphenylbutyryl)pyrrolidine, and its molecular formula: C25H32N2O2, with an atomic weight of ~392.5. Dextromoramide was discovered during the course of research into a related family of compounds, the α,α-Diphenyl-γ-Dialkyamino-Butyramides, which show no analgesic activity, but are extremely active physiologically as inhibitors of gastric secretions in man. Other drugs from this series show antispasmodic and antihistamine effects, but most research was put into researching analgesics. The structure-activity relationships of this family of drugs was investigated extensively, with dextromoramide representing the optimisation of several different structural features; (i) at the 1-amide group only the pyrrolidine and dimethylamide substituents were active, with pyrrolidine being more potent (ii) the alkyl chain was more potent when methylated, 3-methylation was more potent than 4-methylation, and in the 3-methyl analogues the dextro isomer was more active (iii) while morpholine, dimethylamine, pyrrolidine and piperidine were all active at the 4-amine group, morpholine was the most active (iv) any substitution on the phenyl rings reduces activity.
Unlike depolarizing neuromuscular blockers, non-depolarizing drugs do not produce conformational changes to the receptor. The blockers bind to acetylcholine receptors through a dynamic mechanism, with repeated association and dissociation. Thus, as the concentration of antagonists increases, the concentration of binding subsequently increases. Effective neuromuscular block by non-depolarizing neuromuscular drugs occurs only when 70-80% of acetylcholine receptors are occupied by the drug. This is because at this occupancy rate, junctional potential cannot reach the threshold value required for muscle contraction.The main difference between the two major classes of neuromuscular blocking agents is their respective reversal process of paralyzing effects. Non-depolarizing blockers are reversed through acetylcholinesterase inhibitor drugs which increase the concentration of acetylcholine. Acetylcholine behaves as competitive antagonists on acetylcholine receptors, reducing the binding of non-depolarizing blockers. Whereas, depolarizing blockers that mimic acetylcholine would have increased pharmacological effects when administered alongside acetylcholinesterase inhibitors. Therefore, inhibition reversal for depolarizing neuromuscular blockers occurs naturally within a specific period, after half-life has been achieved. Acetylcholinesterase and butyrylcholinesterase inhibitors: Both cholinesterase inhibitors share similar mechanisms of action. The active site of cholinesterase's consists of an anionic site and an esteric site.
Fish and Wildlife Service declares 23 species extinct, due to a combination of development, invasive species, logging and pollution. September 30 Britney Spears' father Jamie Spears is formally suspended as the conservator of her estate. President Biden signs legislation that would extend funding for the U.S. government through December 3, thereby avoiding a government shutdown. Government funds were due to run out at midnight.
=== Hydrophobic interaction chromatography === Hydrophobic Interaction Chromatography (HIC) is a purification and analytical technique that separates analytes, such as proteins, based on hydrophobic interactions between that analyte and the chromatographic matrix. It can provide a non-denaturing orthogonal approach to reversed phase separation, preserving native structures and potentially protein activity. In hydrophobic interaction chromatography, the matrix material is lightly substituted with hydrophobic groups. These groups can range from methyl, ethyl, propyl, butyl, octyl, or phenyl groups. At high salt concentrations, non-polar sidechains on the surface on proteins "interact" with the hydrophobic groups; that is, both types of groups are excluded by the polar solvent (hydrophobic effects are augmented by increased ionic strength). Thus, the sample is applied to the column in a buffer which is highly polar, which drives an association of hydrophobic patches on the analyte with the stationary phase. The eluent is typically an aqueous buffer with decreasing salt concentrations, increasing concentrations of detergent (which disrupts hydrophobic interactions), or changes in pH. Of critical importance is the type of salt used, with more kosmotropic salts as defined by the Hofmeister series providing the most water structuring around the molecule and resulting hydrophobic pressure. Ammonium sulfate is frequently used for this purpose. The addition of organic solvents or other less polar constituents may assist in improving resolution.
== Chemical approaches == Nüchter et al. (2001) have shown a new approach to Fischer glycosidation. Employing a microwave oven equipped with refluxing apparatus in a rotor reactor with pressure bombs, Nüchter et al. (2001) were able to achieve 100% yield of α- and β-D-glucosides. This method can be performed on a multi-kilogram scale.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.